Adiponectin Signaling Regulates Skeletal Physiology

Abstract

Bone remodelling is important to maintain the skeletal physiology. Bone loss with aging and hormonal pathologies may be result of
altered bone remodelling leading to osteoporosis. Even in presence of existing therapies, there is an unmet clinical need to look for
ideal alternatives that would stimulate bone formation and keep resorption in check. Adiponectin and its derivatives could be a possible
candidate for such therapy. Orally active small molecule AdipoR agonists may be a proposed solution for this.